DexCom, Inc. (DXCM) Guidance & Earnings Results

On 2026-07-30 DexCom, Inc. raised guidance: "FY2026 revenue raised to $5.18-5.25B (approx 11-13% growth); Non-GAAP gross profit margin ~64%; Non-GAAP operating margin ~23.5-24%; Adjusted EBITDA margin…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

DXCMDexCom, Inc.Follow DXCM — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 29.4B
P/E TTM: 30.9
Dividend yield: —
52-week: —
Next earnings: 10 Feb, in 109 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
30 Jul 26	Raised	FY2026 revenue raised to $5.18-5.25B (approx 11-13% growth); Non-GAAP gross profit margin ~64%; Non-GAAP operating margin ~23.5-24%; Adjusted EBITDA margin ~31.5-32%. · full year
30 Apr 26	Raised	Non-GAAP Operating Margin raised to ~23-23.5% (from prior ~22-23%); Adjusted EBITDA Margin raised to ~31-31.5% (from prior ~30-31%). Revenue guidance reiterated at $5.16-$5.25B. · full year
12 Feb 26	Raised	FY2026 revenue $5.16-$5.25B, 11-13% growth; operating margin 22-23%; EBITDA margin 30-31%. · full year
12 Jan 26	Raised	Initial FY2026 guidance provided · full year
30 Oct 25	Raised	FY2025 revenue $4.630-$4.650 billion (~15% growth) · full year
30 Jul 25	Raised	FY2025 revenue raised to $4.600-4.625B (14-15% growth); non-GAAP gross margin ~62%; non-GAAP operating margin ~21%; adjusted EBITDA margin ~30% · full year

DexCom, Inc. — questions

What guidance did DexCom, Inc. give?: On 2026-07-30: "FY2026 revenue raised to $5.18-5.25B (approx 11-13% growth); Non-GAAP gross profit margin ~64%; Non-GAAP operating margin ~23.5-24%; Adjusted EBITDA margin ~31.5-32%."
When does DexCom, Inc. report earnings?: DexCom, Inc.'s next earnings report is expected on 2027-02-10.

Every figure on this page comes from DexCom, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.